Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Cytomegalovirus Infection After Transplantation: a Study of New Markers to Optimize the Selection of Antiviral Therapies and Reduce the Risk of Developing Direct and Indirect Infection-related Complications (CMV-TX-2025)

Background and Rationale Cytomegalovirus (CMV) remains a major cause of morbidity and mortality in recipients of solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT). Current management relies on antiviral prophylaxis or pre-emptive therapy guided primarily by CMV-DNAemia monitoring. However, recently introduced antivirals such as letermovir and maribavir have changed the virological profile of CMV infection, highlighting limitations of DNAemia as a marker of active viral replication and increasing the need for improved resistance monitoring.

Preliminary studies suggest that CMV-RNAemia (UL21.5 mRNA) may be a more accurate marker of active viral replication and may detect viral clearance approximately 7-14 days earlier than CMV-DNAemia. In parallel, Next Generation Sequencing (NGS) may provide superior detection of antiviral resistance mutations, including low-frequency variants that cannot be identified by conventional Sanger sequencing.

Primary Objective To determine whether using CMV-RNAemia to guide discontinuation of antiviral therapy in transplant recipients can reduce treatment duration and drug-related toxicity without increasing the risk of CMV relapse, compared with the current standard based on CMV-DNAemia.

Secondary Objectives

Compare the diagnostic performance of NGS and Sanger sequencing in detecting CMV antiviral resistance mutations.

Estimate the incidence of resistant or refractory CMV infection (R/R-CMV) in transplant recipients.

Identify risk factors associated with the development of R/R-CMV according to transplant type.

Study Design This is a single-center, pragmatic, randomized controlled interventional study conducted at the IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Adult transplant recipients (≥18 years) with CMV infection requiring antiviral therapy will be randomized (1:1) into two groups:

Experimental arm: antiviral therapy discontinued after two consecutive negative CMV-RNAemia results.

Control arm: antiviral therapy discontinued after two consecutive negative CMV-DNAemia results.

Patients will be followed from treatment initiation, with virological monitoring continuing during therapy and follow-up.

Population and Sample Size The study plans to enroll approximately 330 CMV infection episodes, including an estimated 10% drop-out rate, with 150 participants per study arm plus additional cases to compensate for losses.

Endpoints Primary endpoints include:

Time to treatment discontinuation. Time to viral clearance. Incidence and timing of clinically significant CMV relapse. Antiviral drug toxicity.

Secondary endpoints include:

Sensitivity, specificity, and predictive value of NGS versus Sanger sequencing. Incidence of resistant/refractory CMV infection. Identification of clinical and virological risk factors for resistance.

Resistance Analysis In suspected resistant or refractory CMV infections, residual biological samples will undergo NGS analysis targeting CMV genes involved in antiviral resistance (UL97, UL54, UL56, UL89, UL27, UL51). Results will be compared with standard Sanger sequencing to assess earlier detection of resistance mutations and minor viral variants.

Expected Impact The study aims to establish CMV-RNAemia as a clinically useful marker for earlier identification of viral clearance, enabling shorter antiviral treatment and reduced toxicity. It also seeks to validate NGS-based resistance testing as a more sensitive tool for detecting emerging CMV drug resistance, ultimately supporting a more personalized approach to CMV management in transplant recipients and potentially other immunocompromised populations.

Study Duration and Funding The study is expected to last 24 months (18 months recruitment, 4 months follow-up, 2 months analysis) and is funded by the Italian Ministry of Health (Ricerca Corrente 2026, project RC-2026-2802099).

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

330

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Italy
      • Bologna, Italy, Italia, 40138
        • IRCCS Azienda Ospedaliero-Universitaria di Bologna

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • CSE/SOT transplant patient;
  • Currently receiving antiviral medication;
  • Age ≥ 18 years
  • Signed informed consent form for participation and data processing

Exclusion Criteria:

  • Localized CMV infection / organ disease.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Antiviral therapy will be discontinued after two consecutive negative results for CMV-RNAemia

From enrollment (time 0, t0) until viral clearance is achieved (tn), all remaining biological material from blood samples analyzed for the monitoring/diagnosis of CMV infection will be collected and stored. Plasma samples will be analyzed for the presence of UL21.5 mRNA (CMV-RNAemia UL21.5) using the automated CMV-RNA ELITe MGB kit on an InGenius instrument (ELITech Group).

During the treatment period and the follow-up period, patients will be monitored in accordance with current clinical practice through serial virologic assessments (CMV-DNAemia) and the collection of relevant clinical data. Assessments will be conducted weekly during the first three months after transplantation, every 15 days from the fourth to the sixth month, and then monthly from the seventh to the twelfth month. For the purposes of evaluating the primary endpoint, the first four months of follow-up will be taken into account.

Aktiv komparator: Antiviral therapy will be discontinued after two consecutive negative results for CMV-DNAemia

During the treatment period and the follow-up period, patients will be monitored in accordance with current clinical practice through serial virologic assessments (CMV-DNAemia) and the collection of relevant clinical data. Assessments will be conducted weekly during the first three months after transplantation, every 15 days from the fourth to the sixth month, and then monthly from the seventh to the twelfth month. For the purposes of evaluating the primary endpoint, the first four months of follow-up will be taken into account.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
CMV-DNAemia VS CMV-DNAemia 1
Tidsramme: Periprocedural

To determine whether the use of CMV-RNAemia to guide the discontinuation of antiviral therapy in transplant recipients (SOT and CSE) results in a reduction in the duration of treatment exposure compared to the standard strategy based on CMV-DNAemia, and a possible reduction in toxicity from anti-CMV drugs, without increasing the risk of recurrence of the infection.

Measure: Time to discontinuation of therapy

Periprocedural
CMV-DNAemia VS CMV-DNAemia 2
Tidsramme: Periprocedural

To determine whether the use of CMV-RNAemia to guide the discontinuation of antiviral therapy in transplant recipients (SOT and CSE) results in a reduction in the duration of treatment exposure compared to the standard strategy based on CMV-DNAemia, and a possible reduction in toxicity from anti-CMV drugs, without increasing the risk of recurrence of the infection.

Measure: Time to viral clearance

Periprocedural
CMV-DNAemia VS CMV-DNAemia 3
Tidsramme: Follow-up analysis (up to 4 months)

To determine whether the use of CMV-RNAemia to guide the discontinuation of antiviral therapy in transplant recipients (SOT and CSE) results in a reduction in the duration of treatment exposure compared to the standard strategy based on CMV-DNAemia, and a possible reduction in toxicity from anti-CMV drugs, without increasing the risk of recurrence of the infection.

Measure: Incidence and time to recurrence of clinically significant CMV infection

Follow-up analysis (up to 4 months)
CMV-DNAemia VS CMV-DNAemia 4
Tidsramme: Periprocedural

To determine whether the use of CMV-RNAemia to guide the discontinuation of antiviral therapy in transplant recipients (SOT and CSE) results in a reduction in the duration of treatment exposure compared to the standard strategy based on CMV-DNAemia, and a possible reduction in toxicity from anti-CMV drugs, without increasing the risk of recurrence of the infection.

Measure: Toxicity associated with anti-CMV drugs

Periprocedural

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Sanger sequencing VS NGS sequencing 1
Tidsramme: Follow up analysis (up to 1 year)

Evaluate the diagnostic performance of NGS sequencing compared to the Sanger method in identifying CMV mutations associated with drug resistance, including minor variants.

Measure: Sensitivity and specificity of NGS compared to Sanger

Follow up analysis (up to 1 year)
Incidence of refractory CMV infection
Tidsramme: Follow up analysis (up to 1 year)

To estimate the incidence of resistant or refractory CMV infection (R/R CMV) in transplant recipients (SOT and CSE).

Measure: Incidence of resistant or refractory CMV infection

Follow up analysis (up to 1 year)
Risk factors for refractory CMV infection
Tidsramme: Follow up analysis (up to 1 year)

To compare the risk factors associated with the development of resistant or refractory CMV infection (R/R CMV) by type of transplant.

Measure: Risk factors associated with resistant or refractory CMV infection

Follow up analysis (up to 1 year)
Sanger sequencing VS NGS sequencing 2
Tidsramme: Follow up analysis (up to 1 year)

Evaluate the diagnostic performance of NGS sequencing compared to the Sanger method in identifying CMV mutations associated with drug resistance, including minor variants.

Measure: Predictive value of NGS compared to Sanger

Follow up analysis (up to 1 year)
Sanger sequencing VS NGS sequencing 3
Tidsramme: Follow up analysis (up to 1 year)

Evaluate the diagnostic performance of NGS sequencing compared to the Sanger method in identifying CMV mutations associated with drug resistance, including minor variants.

Measure: Time required to identify mutations using NGS compared to Sanger

Follow up analysis (up to 1 year)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. november 2026

Primær fullføring (Antatt)

1. juni 2028

Studiet fullført (Antatt)

1. juni 2028

Datoer for studieregistrering

Først innsendt

5. november 2026

Først innsendt som oppfylte QC-kriteriene

12. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Andre studie-ID-numre

  • CMV-TX-2025
  • WFR 2802099 (Annet stipend/finansieringsnummer: Italian Ministry of Health)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .